Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Communication on Safety of Medicines in Europe: Current Practices and General Practitioners’ Awareness and Preferences
Sieta T. de Vries, Maartje J. M. van der Sar, Amelia Cupelli, et al.
Drug Safety (2017) Vol. 40, Iss. 8, pp. 729-742
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Impact of medicines regulatory risk communications in the UK on prescribing and clinical outcomes: Systematic review, time series analysis and meta‐analysis
Christopher Weatherburn, Bruce Guthrie, Tobias Dreischulte, et al.
British Journal of Clinical Pharmacology (2019) Vol. 86, Iss. 4, pp. 698-710
Open Access | Times Cited: 37
Enhancing Pharmacovigilance Capabilities in the EU Regulatory Network: The SCOPE Joint Action
Anna Radecka, Louise Loughlin, Mick Foy, et al.
Drug Safety (2018) Vol. 41, Iss. 12, pp. 1285-1302
Open Access | Times Cited: 25
New safety signals assessed by the Pharmacovigilance Risk Assessment Committee at EU level in 2014–2017
Andrea Farcaş, Andreea Măhălean, Noémi Beátrix Bulik, et al.
Expert Review of Clinical Pharmacology (2018) Vol. 11, Iss. 10, pp. 1045-1051
Closed Access | Times Cited: 25
The effectiveness of direct to healthcare professional communication – A systematic review of communication factor studies
Mathias Møllebæk, Susanne Kaae, Marie L. De Bruin, et al.
Research in Social and Administrative Pharmacy (2018) Vol. 15, Iss. 5, pp. 475-482
Open Access | Times Cited: 21
Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States
Alice L Bhasale, Ameet Sarpatwari, Marie L. De Bruin, et al.
Clinical Pharmacology & Therapeutics (2020) Vol. 109, Iss. 6, pp. 1424-1442
Open Access | Times Cited: 20
Safety Communication Tools and Healthcare Professionals’ Awareness of Specific Drug Safety Issues in Europe: A Survey Study
Sieta T. de Vries, Maartje J. M. van der Sar, Anna Marie Coleman, et al.
Drug Safety (2018) Vol. 41, Iss. 7, pp. 713-724
Open Access | Times Cited: 20
Regulatory authority and clinical acceptability: Physicians' responses to regulatory drug safety warnings
Alice L Bhasale, Ameet Sarpatwari, Wendy Lipworth, et al.
British Journal of Clinical Pharmacology (2021) Vol. 88, Iss. 2, pp. 713-722
Open Access | Times Cited: 13
Challenges in the Implementation of EU Risk Minimisation Measures for Medicinal Products in Clinical Practice Guidelines: Mixed Methods Multi-Case Study
Mathias Møllebæk, Helga Gardarsdóttir, Alexia Bikou, et al.
Drug Safety (2024) Vol. 48, Iss. 2, pp. 161-177
Open Access | Times Cited: 1
A description of medicines-related safety issues evaluated through a referral procedure at the EU level after 2012
Andreea Farcaș, Teodora Balcescu, Laura Alexandra Anghel, et al.
Expert Opinion on Drug Safety (2020) Vol. 19, Iss. 6, pp. 755-762
Closed Access | Times Cited: 11
Communicating emerging risks of SGLT2 inhibitors—timeliness and transparency of medicine regulators
Alice L Bhasale, Barbara Mintzes, Ameet Sarpatwari
BMJ (2020), pp. m1107-m1107
Closed Access | Times Cited: 9
Are Drug Safety Advisories Compatible with Physicians’ Information Behaviour?
Mathias Møllebæk, Susanne Kaae
European Journal of Health Communication (2022) Vol. 3, Iss. 3, pp. 1-17
Open Access | Times Cited: 6
Regulatory experience of handling Risk Management Plans (RMPs) for medicinal products in the EU
Dianne Butler, Katarina Vučić, Sabine M. J. M. Straus, et al.
Expert Opinion on Drug Safety (2021) Vol. 20, Iss. 7, pp. 815-826
Closed Access | Times Cited: 8
Design and Evaluation of a Prescription Drug Monitoring Program for Chinese Patent Medicine based on Knowledge Graph
Wangping Xiong, Cao Jun, Xian Zhou, et al.
Evidence-based Complementary and Alternative Medicine (2021) Vol. 2021, pp. 1-8
Open Access | Times Cited: 8
What can we learn from the public’s understanding of drug information and safety? A population survey
Esther Salgueiro, Cristina Gurruchaga, Francisco J. Jimeno, et al.
International Journal of Pharmacy Practice (2018) Vol. 27, Iss. 1, pp. 96-104
Open Access | Times Cited: 8
Evaluation of the effectiveness of risk minimization measures for trimetazidine: A cross sectional joint PASS survey among physicians in selected European countries
Dorothea von Bredow, Massoud Toussi, Abdus Samad, et al.
Pharmacoepidemiology and Drug Safety (2018) Vol. 27, Iss. 12, pp. 1385-1392
Closed Access | Times Cited: 7
Workshop on the Italian Pharmacovigilance System in the International Context: Critical Issues and Perspectives
Janet Sultana, Ugo Moretti, Antonio Addis, et al.
Drug Safety (2018) Vol. 42, Iss. 5, pp. 683-687
Closed Access | Times Cited: 7
Prescribing Variation in General Practices in England Following a Direct Healthcare Professional Communication on Mirabegron
Frank Moriarty, Shegufta Razzaque, Ronald McDowell, et al.
Journal of Clinical Medicine (2018) Vol. 7, Iss. 10, pp. 320-320
Open Access | Times Cited: 6
Preparation of Direct Healthcare Professional Communication: An Exploratory Study on the Experiences and Perceptions of European Pharmaceutical Companies and the EMA
Arnela Boskovic, Mathias Møllebæk, Susanne Kaae
Therapeutic Innovation & Regulatory Science (2019), pp. 216847901987104-216847901987104
Closed Access | Times Cited: 6
Effectiveness of Risk Minimization Measures to Prevent Pregnancy Exposure to Mycophenolate-Containing Medicines in Europe
Terri Madison, Barbara Donner, Roger Mutter, et al.
Pharmaceutical Medicine (2019) Vol. 33, Iss. 5, pp. 395-406
Closed Access | Times Cited: 6
Handling of New Drug Safety Information in the Dutch Hospital Setting: A Mixed Methods Approach
Esther de Vries, Elisabeth Bakker, Remy D. C. Francisca, et al.
Drug Safety (2022) Vol. 45, Iss. 4, pp. 369-378
Open Access | Times Cited: 3
Enhancing medication risk communication in developing countries: a cross-sectional survey among doctors and pharmacists in Malaysia
Rema Panickar, Zoriah Aziz, Adeeba Kamarulzaman
BMC Public Health (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 3
Factors influencing the implementation of medicine risk communications by healthcare professionals in clinical practice: A systematic review
Amal Bandar Alharbi, Ilhem Berrou, Nkiruka Umaru, et al.
Research in Social and Administrative Pharmacy (2022) Vol. 19, Iss. 1, pp. 28-56
Open Access | Times Cited: 3
Assessment of pharmacovigilance guidelines in the Southern African Development Community: A document review
Nokuthula L. Makhene, Hanlie Steyn, Martine Vorster, et al.
Pharmacoepidemiology and Drug Safety (2024) Vol. 33, Iss. 2
Open Access
A quantitative investigation in a territory of Italy on citizens’ attitudes towards medicines through the COVID-19 pandemic: the importance of possible indirect effects caused by the pandemic
Antonio Mastino, Francesca Pettinau, Piergiorgio Palla, et al.
Journal of Pharmaceutical Policy and Practice (2024) Vol. 17, Iss. 1
Open Access
Medicines safety information from regulators in clinical practice guidelines: a mixed-method case study
Armin Andersen, Mathias Møllebæk, Anna Birna Almarsdóttir
Journal of Pharmaceutical Health Services Research (2024) Vol. 16, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top